National Vision Holdings Highlights Nordic Pharma's LACRIFILL Gel Launch at AAO Annual Meeting

Nordic Pharma Unveils LACRIFILL Canalicular Gel at AAO Annual Meeting

Nordic Pharma, Inc. showcases its innovative LACRIFILL Canalicular Gel at the American Academy of Ophthalmology (AAO) Annual Meeting in Orlando, Florida, from October 18-20, 2025. This novel product aims to address the prevalent issue of dry eye symptoms, a significant concern in ophthalmic care. The company highlights compelling patient data, revealing that an impressive 98.11% of both first-time and repeat patients express a willingness to return for future doses of LACRIFILL. This statistic, shared by Jai Parekh, MD, MBA, Chief Commercial Officer of Eye Care U.S., underscores the positive reception and potential for improved patient experiences associated with the gel.

The importance of preoperative dry eye management is further underscored by a collaborative article titled "Critical Perspectives," authored by leading ophthalmologists Vance Thompson, MD, Kayla Karpuk, OD, and Mark Packer, MD. This publication focuses on lacrimal occlusion in the context of cataract and refractive surgeries, emphasizing the necessity of managing dry eye symptoms before surgical procedures. LACRIFILL offers a substantial advantage by being effective for up to six months, providing consistent support for patients both before and after surgical interventions, thereby enhancing overall outcomes.

Nordic Pharma also positions itself as a champion for diversity and empowerment within the ophthalmology field by sponsoring the Women in Ophthalmology (WIO) Awards Ceremony at the AAO. This sponsorship reflects the company’s commitment to fostering a more inclusive environment in the industry. Attendees at the meeting are invited to visit booth #1401 for live injection demonstrations and to place orders for the canalicular gel, further promoting education and awareness surrounding innovative treatment options for dry eye management.

In addition to its focus on LACRIFILL, the recent findings from the TFOS Dry Eye Workshop III report enhance the credibility of Nordic Pharma's offerings. The report cites two studies that demonstrate significant improvements in corneal staining and Schirmer test scores when using the canalicular filler, marking a clear advantage over traditional hydrogel canalicular plugs. This ongoing research and development reinforce Nordic Pharma's commitment to advancing treatment methodologies in the ophthalmic sector. As the company continues to lead in innovative solutions, the AAO Annual Meeting serves as a pivotal platform for sharing these advancements with the broader medical community.